TORONTO, March 6, 2025 /CNW/ – Regeneron Canada Company announced today that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for the reimbursement of Libtayo® (cemiplimab for injection) for advanced non-small cell lung cancer (NSCLC). The Letter of Intent (LOI) was signed on March 3, 2025, which sets the terms of the funding agreement between the pCPA and Regeneron and allows provincial and territorial governments to decide on public reimbursement for their jurisdictions.
“Having a broader range of treatment options for advanced NSCLC is essential,” said Shem Singh, Executive Director for Lung Cancer Canada. “We are pleased to see these negotiations move one step closer to expanding the tools in our arsenal to treat appropriate patients.”
The LOI supports potential reimbursement for adult patients in approved Libtayo indications, as follows1,2:
- As monotherapy for first-line treatment of locally advanced or metastatic NSCLC expressing PD-L1 in ≥50% of tumour cells as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, who have an ECOG Performance Status Scale grade of 0 or 1; and whose metastases to the central nervous system, if present, are treated and stable.
- In combination with platinum‐based chemotherapy for first‐line treatment of locally advanced or …
